The female hormone progesterone (P4) promotes the expansion of stem-like cancer cells in estrogen receptor (ER)-and progesterone receptor (PR)-positive breast tumors. The expanded tumor cells lose expression of ER and PR, express the tumorinitiating marker CD44, the progenitor marker cytokeratin 5 (CK5) and are more resistant to standard endocrine and chemotherapies. The mechanisms underlying this hormone-stimulated reprogramming have remained largely unknown. In the present study, we investigated the role of microRNAs in progestin-mediated expansion of this dedifferentiated tumor cell population. We demonstrate that P4 rapidly downregulates miR-29 family members, particularly in the CD44 þ cell population. Downregulation of miR-29 members potentiates the expansion of CK5 þ and CD44 þ cells in response to progestins, and results in increased stem-like properties in vitro and in vivo. We demonstrate that miR-29 directly targets Krü ppel-like factor 4 (KLF4), a transcription factor required for the reprogramming of differentiated cells to pluripotent stem cells, and for the maintenance of breast cancer stem cells. These results reveal a novel mechanism, whereby progestins increase the stem cell-like population in hormone-responsive breast cancers, by decreasing miR-29 to augment PR-mediated upregulation of KLF4. Elucidating the mechanisms whereby hormones mediate the expansion of stem-like cells furthers our understanding of the progression of hormone-responsive breast cancers.
INTRODUCTION
The role of progesterone (P4) in the mammary gland is complex, as it mediates both proliferation and differentiation. Progesterone receptor (PR) is indispensable for normal mammary ductal side branching and lobulo-alveolar development, 1 yet progestins also have a deleterious role during breast cancer development and progression. 2, 3 In rodent models, P4 accelerates carcinogeninduced mammary tumorigenesis, and PR is critical for this transformation. 4 In women, inclusion of progestins in postmenopausal hormone therapy regimens increases the risk of breast cancer. [5] [6] [7] Progestins increase the number of murine mammary stem cells, 8, 9 normal human breast progenitor cells 10 and stem-like cells in human breast tumor xenografts. 11 Thus, progestin-mediated expansion of stem cell populations may explain its detrimental effects in breast carcinogenesis.
The mechanisms by which progestins increase the stem cell compartment in the normal and malignant breast may include both paracrine and autocrine signals. In the normal mammary gland, P4 acts in a paracrine manner to expand the basal/stem cell populations, and in rodents, this is likely mediated through RANKL. 12 In human breast cancer cells, evidence points to an autocrine mechanism by which progestins directly convert estrogen receptor (ER)-and PR-positive cells to receptornegative cells (ER À PR À ) that acquire expression of the tumorinitiating marker CD44 and cytokeratin 5 (CK5).
11 CK5 þ cells in the normal human breast represent a bi-potent progenitor fraction capable of generating myoepithelial (smooth muscle actin SMA þ ) or luminal epithelial (CK8/18 þ ) lineages. 13 Furthermore, the expression of significant amounts of CK5/CK6 in primary human breast cancers correlates with high grade and worse prognosis. 16 and may be the reason that such tumors can recur many years post-treatment. However, virtually nothing is known about the mechanisms by which progestins reprogram ER þ PR þ CK5 -cells into ER -PR -CK5 þ cells. Non-coding regulatory RNAs termed microRNAs (miRNAs) control various processes important for breast cancer progression and metastasis. Evidence suggests that miRNAs contribute to preserving the 'stemness' of embryonic stem cells, because embryonic stem cells deficient in miRNA processing cannot be maintained. 17 MiRNAs have been implicated in the maintenance of the cancer stem cell (CSC) phenotype via their ability to affect multiple pathways, including those regulating cell proliferation, 18 cell death, [19] [20] [21] cell-cell communication and cell adhesion. 22 MiRNAs can be regulated by hormones and target hormone receptors (reviewed in Tesel et al. 23 and Cochrane et al. 24 ) and have a key role in the acquisition of resistance to hormonaltherapy. [25] [26] [27] Importantly, forced expression of certain miRNAs can revert human somatic (normal skin keratinocytes and hair melanocytes) and cancer cells (cancerous melanoma Colo-829 and prostate cancer PC3 cells) into pluripotent stem cells.
We recently discovered that progestins regulate multiple miRNAs in breast cancer cells. 30 Thus, we hypothesized that P4-regulated miRNAs might have a role in the expansion of CK5
Here we demonstrate that P4 downregulates miR-29 family members, particularly in the CD44 þ population expanded by progestins. Downregulation of miR-29 members potentiates the expansion of CK5 þ and CD44 þ cells in response to P4, resulting in increased mammosphere formation in vitro and increased tumor-initiating capability in vivo. We find that miR-29 directly targets Krü ppel-like factor 4 (KLF4, EZF, GKLF4), a transcription factor necessary for the reprogramming of differentiated cells into pluripotent stem cells and the maintenance of breast CSCs. [31] [32] [33] Thus, both miR-29 downregulation and KLF4 upregulation contribute to maximal expansion of CK5 þ cells in response to progestins in the ER þ PR þ breast cancer cells. These results provide a mechanism by which hormonal control of a potent reprogramming transcription factor mediates the expansion of a population of cells with stem-like properties in the ER þ PR þ breast tumors.
RESULTS

Natural and synthetic progestins induce the expansion of CK5
To determine the extent of CK5 þ cell expansion, we treated T47D and BT474 breast cancer cell lines with progestins and measured the relative amount of CK5 þ cells. T47D cells express PR in the absence of estrogen stimulation, whereas BT474 represent the majority of ER þ breast cancer cell lines that require pre-treatment with estrogens to induce PR expression. The natural hormone P4, and the synthetic progestins medroxyprogesterone acetate (MPA) and R5020, equally promote the expansion of the CK5 þ population from o1 to B20% in T47D cells (Figure 1a , top). BT474 cells were pretreated for 48 h with 10 nM 17b-estradiol (E2) to induce PR expression, and subsequently treated with either vehicle or 100 nM progestins for 24 h. The CK5 þ population increased from o1% to B5% compared with vehicle-treated BT474 cells (Figure 1a, bottom) . Time-course analyses show that CK5 mRNA levels increase during the first 24 h after progestin stimulation in both cell lines (Figure 1b and Supplementary Figure 1A) . The degree to which progestins increase CK5 mRNA levels and the number of CK5 þ cells varies in different ER þ cell lines (Figure 1b (right) and Supplementary Figure 1B) .
As most CK5 þ cells are also CD44 þ , 11, 34 we also determined if P4 would increase the CD44 þ population in breast cancer cells. T47D cells were treated with vehicle or P4, and the CD44 content analyzed by flow cytometry. P4 increased the percentage of CD44 þ cells from 3.8 ± 2.3 to 22.75 ± 15.18% (Po0.001) (Supplementary Figure 1C) . This level is comparable to the P4-mediated increase in CK5 þ cells. MiR-29a, b and c are lost in aggressive non-small cell lung cancers and melanomas; 35-37 thus, we sought to determine whether loss of miR-29 has a role in the P4-mediated expansion of more dedifferentiated breast cancer cells. Time-course experiments demonstrated that treatment of T47D cells with 100 nM P4 decreases the expression levels of mature miR-29 family members as early as 6 h after P4 treatment (Figure 1c) . Likewise, BT474 cells treated for 48 h with E2, followed by stimulation with P4 showed a similar decrease in miR-29 levels (Figure 1c and Supplementary Figure 2) . MiR-29 levels return to basal levels by 24 h in T47D cells. 27 In the previous experiments, miRNA levels were measured in a mixed population (the minority CD44 þ CK5 þ plus the majority CD44 À CK5 À cells). To determine the expression of each miR-29 member specifically in the CD44 þ population, we treated T47D cells with vehicle or P4 for 24 h, and isolated the CD44 hi and CD44 lo populations by fluorescence-activated cell sorting (Figure 1d, top) . Quantitative reverse-transcriptase PCR showed that expression of mature miR-29a, b and c were all significantly reduced in CD44 hi compared with CD44 lo cells (Figure 1d , bottom). Human miR-29 family members are encoded by the miR-29b-1/ miR-29a cluster and the miR-29b-2/miR-29c cluster. 38 As miR-29a was relatively more abundant than miR-29b or miR-29c in both cell lines analyzed, we sought to determine the mechanism of P4-mediated downregulation of the miR-29a/b1 locus. P4 downregulated pri-miR-29a as early as 1 h post-treatment (Figure 2a) . The miR-29a/b1 promoter is repressed by c-Myc in stem cells, 39 and progestins rapidly upregulate c-Myc
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( Figure 2b ), suggesting that P4-induced downregulation of miR29a could be mediated by c-Myc. Consistent with this hypothesis, siMYC prevented the early upregulation of c-Myc in response to P4 (Figure 2b ) and abrogated the ability of P4 to downregulate miR-29a in T47D ( Figure 2c ) and BT474 cells (Supplementary Figure 3A) . siMYC also abolished P4-mediated downregulation of pri-miR-29a ( Figure 2c and Supplementary Figure 3A) . Upregulation of c-Myc and downregulation of miR-29a by P4 were abrogated by the PR antagonist RU486 (Figure 2d and Supplementary Figure 3B ). Furthermore, P4 did not affect levels of miRNA-processing enzyme Dicer in T47D cells (Supplementary Figure 3C) , suggesting that miR-29a downregulation is not the result of decreased global miRNA processing. Taken together, these data suggest that the PR-dependent repression of miR-29a is transcriptional and likely mediated by c-Myc. (Figures 3a and b) . However, inhibition of miR-29a, compared with SCR-ZIP control, significantly augmented the P4-mediated increase in CD44 þ and CK5 þ cells as analyzed by flow cytometry (Figure 3a ) and immunocytochemistry ( Figure 3b ). In agreement with the finding that miR-29a is the most abundant member of this family in breast cancer cells and likely to represent the major functional factor, inhibition of miR-29b and c did not significantly increase the CD44 þ population (Figure 3a) or the CK5 þ population (data not shown) in either the absence or presence of P4.
To test whether miR-29 has a role in self-renewal of stem-like cells in ER þ breast cancer cells, we cultured T47D and BT474 cells expressing either SCR-ZIP, 29aZIP, 29bZIP and 29cZIP in threedimensional Matrigel colony-forming assays (Figure 3c ). SCR-ZIP control cells formed colonies at significantly lower frequencies than 29aZIP cells in both T47D and BT474 cell lines (Figure 3c , right). In addition, 29aZIP cells formed more colonies that were larger than 60 mm in diameter as compared with those in the SCR-ZIP controls (Figure 3c , right). 29bZIP and 29cZIP cells also formed significantly more colonies than the SCR-ZIP cells, but to a lesser extent than 29aZIP cells.
We next evaluated the ability of SCR-ZIP and 29aZIP cells to initiate tumors by injecting cells pretreated for 24 h with vehicle (OH) or 100 nM P4 in vitro into the fourth mammary gland of miR-29 and reprogramming of breast cancer cells DM Cittelly et al female nude (nu/nu) mice at dilutions ranging from 10 3 to 10 5 . All mice were supplemented with estradiol (necessary for tumor growth in vivo). Table 1 summarizes limiting dilution experiments. 29aZIP cells were able to form tumors in mice more efficiently when compared with the SCRZIP cells in both the vehicle and P4-treated groups (Table 1) . However, this was most pronounced in the P4-treated groups, where 29aZIP cells form palpable tumors in 9/10 animals, whereas SCR-ZIP cells grew in 4/10 mice. Collectively, these data indicate that suppression of miR-29a potentiates tumor-initiating ability.
Inhibition of miR-29a promotes tumor growth in vivo
To investigate the role of miR-29a inhibition in tumor growth in vivo, we injected T47D SCRZIP and T47D 29aZIPs (1 Â 10 6 cells) in the contralateral fourth mammary fat pad of non-obese diabetic/SCID mice. Mice were supplemented with E2 alone or estradiol plus progestin (E2 þ MPA). Tumors produced by 29aZIP cells were significantly larger than those produced by SCR-ZIP cells, in both E2 alone or E2 þ MPA-treated mice (Figures 4a and b). Tumors in mice treated with MPA were significantly smaller than those of E2-treated mice, although Ki67 staining did KLF4 is upregulated by P4 and is a direct target of miR-29 KLF4, which encodes KLF4, is a predicted target of miR-29, and is required for induction of pluripotent stem cells, 41 self-renewal of embryonic stem cells and maintenance of breast CSCs. 32 In addition, KLF4 is upregulated by P4 via PR in T47D cells. 42 To determine if KLF4 is involved in the promotion of CK5 þ cells in response to P4, we performed time-course analysis of KLF4 expression in T47D cells following P4 stimulation. KLF4 mRNA and protein levels increased rapidly after P4 stimulation ( Figures 5a  and b) ; at the same time, decreases in miR-29a were observed (Figure 1c) . The increase in KLF4 preceded the promotion of CK5 þ cells in response to P4 (Figure 5b) , and CD44 hi cells isolated from P4-treated T47D cells showed significantly higher KLF4 and CK5 mRNA levels ( Figure 5c ). To determine whether KLF4 is a direct target of miR-29, we cloned the KLF4 3 0 -untranslated region (UTR) containing the predicted miR-29-binding site downstream of luciferase in a reporter construct and measured luciferase activity in presence of miR-29 mimic. The predicted binding site for miR-29a and b in the KLF4 3 0 -UTR is depicted in Figure 6a (left). As transfection of miR-29 can activate p53 and induce apoptosis at low concentrations, 43 we normalized our luciferase reporter experiments to the expression of a non-targetable Renilla control. As KLF4 is targeted by miR-200c, 44 we therefore used exogenous miR-200c as a control to repress KLF4 3 0 -UTR. As shown in Figure 6a (middle), miR-29a, miR-29b and miR-200c mimics decreased luciferase activity to a similar extent, and blocking miR-29 by adding miR-29a inhibitor blocked this effect. These results demonstrate direct targeting of the KLF4 3 0 -UTR by both the miR-200c and miR-29 family. To further demonstrate that downregulation of miRNAs by P4 regulates the KLF4 3 0 -UTR, we transfected the luciferase reporter containing the KLF4 3 0 -UTR into . P4 treatment increased luciferase activity from the KLF4-3 0 -UTR and this effect was partially blocked by adding miR-29a mimic (Figure 6a, right) . This indicates that the P4-mediated decrease in an miRNA, specifically miR-29a, relieved targeting of the KLF4-3 0 -UTR resulting in an increase in luciferase activity. Neither P4 nor the miR-29a mimics affected luciferase expression in the vector control (Supplementary Figure 4) . These data support that KLF4 expression depends on the balance between transcriptional activation (by PR) and posttranscriptional repression (by miR-29). To decipher the contribution of miR-29 to the repression of KLF4 in luminal breast cancer cells, we quantified KLF4 protein levels in 29aZIP T47D and BT474 cells in the absence and presence of P4 (Figure 6b ). Compared with SCR-ZIP controls, 29aZIP cells had increased baseline levels of KLF4 in both T47D and BT474 cell lines, suggesting that repression of KLF4 translation by miR-29 has a role in maintaining low KLF4 levels in the absence of P4 (Figure 6b) . Furthermore, P4 stimulation resulted in significantly higher KLF4 levels in 29aZIPs cells.
To further unveil the role of miR-29a in the regulation of KLF4 expression, we overexpressed miR-29a in T47D and BT474 cells, using a lentiviral vector carrying its precursor sequence (pre-miR-29a). Western blot analyses showed that miR-29a significantly blocked the upregulation of KLF4 in response to P4 in T47D and BT474 cells (Figure 6c ), indicating that blocking the P4-mediated downregulation of miR-29a by addition of excess miR-29a precursor limits the amount of KLF4 protein induced by P4. To measure the contribution of KLF4 and miR-29 on expression of the CK5 þ promoter, we used T47D cells stably expressing a luciferase reporter driven by the human KRT5-promoter (KRT5-luciferase). In this system, there is no direct repression of luciferase through the 3 0 -UTR; thus, the luciferase activity is an indirect measure of the CK5 promoter activation in CK5 þ cells. P4 stimulation led to a significant activation of KRT5-luciferase, which was blocked by the P4 antagonist RU486 (Supplementary Figure 5) . Transient overexpression of miR-29a and b (using miRNA mimics) or KLF4 inhibition (using siKLF4) resulted in significantly lower KRT5-luciferase activation in response to P4 compared with vehicle control (Figure 7a) . Furthermore, western blot analysis showed that partial knockdown of KLF4 expression using small interefering RNA decreased CK5 levels after 24 h P4 treatment (Figure 7b ) and significantly decreased the percentage of CD44 þ cells basally and in response to P4 (Figure 7c ) in T47D cells. Taken together, these results demonstrate that KLF4 upregulation and miR-29 downregulation contribute to the maximal expansion of the stem-like population by progestins.
DISCUSSION
In cancers, acquisition of stem-like phenotype can occur through multiple means, including epithelial to mesenquimal transition, selection during prolonged therapy or local and systemic signals. This study identified a novel mechanism by which progestins stimulate the expansion of breast cancer stem-like cells by both direct and miRNA-mediated control of a potent reprogramming factor, KLF4.
MiR-29 family members are downregulated in many human cancers as compared with their normal tissue of origin, 36, 45, 46 including invasive breast cancer. 47 Expression of miR-29 is associated with more differentiated luminal-subtype human and mouse mammary tumors, and is repressed in less-differentiated basal-like tumors. 48, 49 Similarly, we demonstrate that a decrease in miR-29 levels has a role in the progestin-mediated acquisition of more de-differentiated CD44 þ /CK5 þ cells. Thus, alterations in miRNA expression constitute one downstream molecular mechanism by which P4 cues cancer cell de-differentiation.
The three miR-29 mature forms are predicted to target the same mRNAs due to the homology in their seed sequence. We found that miR-29a is the most abundant of the three mature forms in luminal breast cancer cells and the most decreased in the CD44 þ cell fraction, suggesting that miR-29a might have the major functional role in the P4-mediated expansion of the CD44 þ fraction. In support of this hypothesis, inhibition of miR-29a significantly potentiated the increase in CD44 þ and CK5 þ cells in response to P4, whereas inhibition of miR-29b or miR-29c did not. Furthermore, miR-29a is more stable than miR-29b in cycling cells, 38, 50 which could also explain the relatively high abundance of miR-29a.
Decreased levels of mature miR-29 correlated with lower levels of miR-29 precursors, suggesting that miR-29 downregulation results from transcriptional suppression. c-Myc downregulates miR-29a to enhance reprogramming of mouse embryonic fibroblasts. 51 Indeed, we demonstrate that progestin downregulation of miR-29a is transcriptional and also mediated by c-Myc. C-Myc was transiently upregulated by progestins during the first 1 h and returned to basal levels by 3 h in T47D cells. This parallels the early downregulation of miR-29a after P4 treatment and its return to basal levels by 24 h. Likewise, c-Myc upregulation lasted longer (6 h) and resulted in more marked miR-29 repression in BT474 cells. Early and transient expression of c-Myc effectively initiates cellular reprogramming to induced-pluripotent stem cells, but is dispensable at later stages in mature induced-pluripotent stem cells. 52 Our data indicate that similar to c-Myc, early downregulation of miR-29a in response to progestins is involved in reprogramming of luminal breast cancer cells.
Sustained miR-29 inhibition increased tumor growth, indicating that miR-29 acts as tumor suppressor in T47D cells in vivo. Tumor suppressor roles attributed to miR-29 include reduction of cell proliferation, 37 induction of apoptosis, 39 and decreased cancer cell invasion and metastasis by targeting extracellular matrix proteins. 36 MiR-29 repression did not correlate with increased proliferation in vivo as determined by Ki67 staining, suggesting that the increased growth of 29aZIP tumors results, at least in part, from their increased tumor-initiating ability. Indeed, sustained miR-29 repression resulted in increased mammosphere formation in vitro and tumor-initiating ability in vivo, suggesting that the small but statistically insignificant increase in the CD44 þ cells in ER þ PR þ breast cancer. KLF4 is highly expressed in CSC-enriched populations in breast cancers, and KLF4 knockdown results in decreased tumorigenesis. 32 P4 directly upregulates KLF4 in T47D cells, 42 indicating that KLF4 expression involves both transcriptional and post-transcriptional regulation. Importantly, P4 treatment is sufficient to relieve repression of the KLF4 3 0 -UTR, corroborating that suppression of miRNAs targeting KLF4 significantly facilitates the progestin-mediated increase in KLF4 expression. We recently reported a similar mechanism for other genes transcriptionally regulated by liganded-PR binding to the promoter, and post-transcriptionally controlled via downregulation of miRNAs targeting their 3 0 -UTR. 30 It is interesting that a potent reprogramming transcription factor for normal cells might also cause reprogramming in cancers. KLF4 directly activates telomerase activity in human embryonic stem cells and CSCs. 31 Additionally, in breast cancer cells, KLF4 maintains the stem cell phenotype and increases cell motility via activation of the Notch pathway. 32 Further studies are necessary to determine if these or other pathways activated by KLF4 have a role in the promotion of CK5 þ cells. In this study, stable miR-29 inhibition alone was not sufficient to induce CK5 þ cells in the absence of progestins, suggesting that progestin-mediated transcriptional activation of KLF4 (and perhaps additional factors) is necessary for the induction of the CK5 þ population. Transient inhibition of the pluripotent factor c-Myc did not significantly affect the promotion of CD44 þ cells by P4 (not shown), indicating that c-Myc is not solely responsible for this reprogramming. Recently KLF5, another KLF family member upregulated by P4 was found to partially mediate the increase of CK5 þ cells in T47D cells in vitro. 53 Our finding that KLF4 knockdown or miR-29 overexpression diminishes the P4-mediated CK5 promoter activation and increase in CD44 þ cells indicates that upregulation of KLF4 and repression of miR-29 by P4 both contribute to the maximal expansion of the stem-like population in luminal breast cancer cells.
In conclusion, progestins upregulate KLF4 at the transcriptional and post-transcriptional level through downregulation of its repressor, miR-29 ( Figure 8 ). miR-29 repression augments the P4-mediated expansion of the CK5 þ CD44 þ population. Other progestin-regulated miRNAs may contribute to progestindependent reprogramming of a subpopulation of cells in ER þ PR þ breast cancers, and we are actively investigating this hypothesis. Understanding the molecular mechanisms by which cancer cells can revert to stem-like state and how hormones affect this process will ultimately help us prevent this undesirable plasticity.
MATERIALS AND METHODS
Cell lines
T47D cells were cultured in Dulbecco's modified Eagle's medium 10% fetal bovine serum, L-glutamine and penicillin/streptomycin. BT474 cells were maintained in RPMI, 5% fetal bovine serum, L-glutamine and penicillin/ streptomycin.
Stable cell lines
Stable inhibition of miR-29a, b or c was obtained with lentiviral vectors expressing complementary sequences to each mature miRNA (pMIRZIPs, System Biosciences, Mountain View, CA, USA). For overexpression, lentiviral vectors carried precursor sequences for miR-29a, miR-29b1 and miR-29c, respectively. A scrambled, non-silencing, SCR-ZIP vector was used as the negative control. Stable expressing cells were selected on the basis of green fluorescent protein-based cell sorting (for pMIRNA vectors) or puromycin selection (miRZIP vectors). 
Flow cytometry
Cells were labeled with antibodies CD44-APC, CD24-PE (BD Biosciences, Franklin Lakes, NJ, USA) at a concentration of 10 Â 10 6 cells per ml under optimized conditions, and were subjected to fluorescence-activated cell sorting analysis and sorting on a Moflo XDP 100 (Beckman-Coulter, Indianapolis, IN, USA). Data analysis was performed using Kaluza Analysis Software (Beckman-Coulter).
RNA extraction and quantitative reverse-transcriptase PCR Total RNA from cultured cell lines was isolated using Trizol. To isolate RNA from sorted cells (o10 000), cells were collected in lysis buffer, and RNA isolated with the RNAqueous-Micro kit (Ambion, Austin, TX, USA) following manufacturer instructions. cDNA from mature miR-29a, miR-29b and miR29c was synthesized using the TaqMan MicroRNA Reverse Transcription Kit (Applied Biosystems, Carlsband, CA, USA) and quantitative reversetranscriptase PCR was performed using TaqMan MicroRNA Assays (Applied Biosystems). RNU6B was used for normalization. cDNA for quantification of pri-miR-29a, CK5 and KLF4 mRNA levels was synthesized using the MuLV reverse transcriptase (Applied Biosystems). b-actin or GAPDH were used for normalization. The relative mRNA or miRNA levels were calculated using the comparative Ct method (DDCt).
Tumor growth and limiting dilution tumor formation in vivo
Tumor xenografts were developed by injecting indicated amount of cells in 50% Matrigel Basement Membrane Matrix (BD Biosciences, San Jose, CA, USA) into the fourth mouse mammary fad pad of ovariectomized female non-obese diabetic/SCID mice (for tumor growth) or nu/nu mice (for limiting dilution experiments (Jackson Labs, Bar Harbor, ME, USA). Pellets containing either estrogen alone (2 mg) or in combination with MPA (10 mg) were implanted subcutaneously at time of tumor cell injection. 54 Tumors were measured weekly using a digital caliper, and tumor volume was estimated using the formula lw 2 /2. At termination of the experiment, mice were killed, and tumors were excised and weighed. These experiments were performed under an approved University of Colorado Institutional Animal Care and Use Committee protocol.
Three-dimensional Matrigel colony-formation assay 
Digital imaging
For immunofluorescence analysis, images were collected using a Nikon digital camera, and the images were exported as tiff files to Adobe Photoshop. Within each figure, minor adjustments were made to brightness and contrast to more accurately portray the appearance of the actual samples. For the experimental and control panels within each figure or subfigure, all manipulations and adjustments were performed identically and in parallel. Within Photoshop, color bitmaps were changed from RGB (red, green, blue) to CMYK (cyan, magenta, yellow, black).
Statistical analysis
Statistics were done using Graphpad Prism version 5.0 d for MacOS, Graphpad software (La Jolla, CA, USA). Two-tailed Student's t-tests or analysis of variance, followed by Bonferroni post hoc tests were used. Po0.05 were considered significant. promoter. T47D cells stably expressing a luciferase reporter driven by the KRT5-promoter were plated at 10 000 cells per well in 96-well plates. After 24 h, cells were transfected with 50 nM miR-29a (29a) or miR-29b mimics or negative control (NC), 5 nM on-target pool siKLF4 or siNC in combination with a renilla-luciferase plasmid (pRL-SV40) using Dual-transfection reagent. Cells were treated for additional 24 h with ethanol (OH) or 100 nM P4, and luciferase activity measured 24 h after transfection and normalized to renilla-luciferase control. *Po0.05 (b) T47D cells were transfected with 5 or 10 nM siKLF4-smart pool or si-NC control in combination with pGFP plasmid to control for transfection efficiency. After 24 h, cells were treated with either ethanol (OH) or 100 nM P4 for 24 h, and western blotting was performed to detect KLF4 and CK5. (c) T47D were transfected with 10 nM siNC or si-KLF4. After 24 h, cells were treated with vehicle (OH) or 100 nM P4 for 24 h, and CD44 
